{"id":"W3157098966","doi":"10.1097/hs9.0000000000000562","title":"Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial","year":2021,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Sierra Oncology; Incyte; Gilead Sciences; CTI Biopharma; Celgene; Sanofi; Bristol-Myers Squibb","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Quality of life (healthcare); Internal medicine; Clinical trial; Population; Physical therapy; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003590806,0.000638513,0.001993223,0.00006525981,0.0003036508,0.00005729188,0.0001006419,0.0002555641,0.0004583766],"category_scores_gemma":[0.0004093006,0.0003630309,0.0002039715,0.0007001377,0.0002525997,0.0001816634,0.00009988011,0.0003805079,0.000004753018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001671717,"about_ca_system_score_gemma":0.0007593193,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002913998,"about_ca_topic_score_gemma":0.001083407,"domain_scores_codex":[0.9949413,0.000512302,0.002187576,0.0009484076,0.0008076667,0.0006027814],"domain_scores_gemma":[0.9962962,0.0005898773,0.001336969,0.000848365,0.0004868973,0.0004417017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02596561,0.006188149,0.9517774,0.0001454139,0.001781077,0.00004580447,0.002882026,0.000004674799,0.0001612053,0.0001213466,0.000183718,0.01074359],"study_design_scores_gemma":[0.1670061,0.01311946,0.8154988,0.0009466852,0.0004273381,0.00000851997,0.0008138987,0.00002301547,0.001721071,0.00002820985,0.00005522185,0.0003517219],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918093,0.001638971,0.000002777063,0.001860573,0.00008724246,0.003950311,0.0002235891,0.00009952437,0.0003276883],"genre_scores_gemma":[0.9969534,0.00008638597,0.0005362889,0.0005680089,0.00002656236,0.0004031449,0.001118796,0.00007964791,0.000227722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1410404,"threshold_uncertainty_score":0.9998822,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02729231896859579,"score_gpt":0.2889486548959623,"score_spread":0.2616563359273665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}